# OnCo record nct06942234 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06942234/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06942234", "NCT06942234" ;
  schema:name "Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer"@en ;
  schema:description "A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06942234/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06942234> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-06-01" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/jskn016/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/alphamab/> .